SCHEMBL2675489

SCHEMBL2675489

N#CCCN1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
LMNA P02545 2/20 0.44
P4HB P07237 1/20 0.40
MAPT P10636 2/20 0.39
HTR7 P34969 4/20 0.38
NPSR1 Q6W5P4 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPK1 P28482 2/20 0.38
TSHR P16473 2/20 0.37
GAA P10253 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.36
RAD52 P43351 1/20 0.36
KMT2A Q03164 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3632605 0.90 ALDH1A1 (0.37) ALDH1A1LMNAP4HBMAPTHTR7
SCHEMBL2677561 0.86 ALDH1A1 (0.42) ALDH1A1LMNAP4HBMAPTHTR7
SCHEMBL2675238 0.86 P4HB (0.51) ALDH1A1LMNAP4HBMAPTHTR7
SCHEMBL2675784 0.85 ALDH1A1 (0.44) ALDH1A1LMNAP4HBMAPTHTR7
SCHEMBL2677324 0.85 MAPT (0.51) ALDH1A1LMNAP4HBMAPTHTR7
SCHEMBL2675842 0.84 HRH3 (0.43) ALDH1A1P4HBMAPTHTR7NPSR1
SCHEMBL2675946 0.84 P4HB (0.45) ALDH1A1P4HBMAPTHTR7NPSR1
SCHEMBL2676679 0.84 NPSR1 (0.50) ALDH1A1LMNAP4HBMAPTHTR7
SCHEMBL2677815 0.84 HTR1A (0.46) ALDH1A1P4HBMAPTSMN1; SMN2MEN1
SCHEMBL2676766 0.84 MCL1 (0.46) ALDH1A1LMNAMAPTHTR7NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ALDH1A1 2304/4885LMNA 4207/4885P4HB 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.